trofinetide
Marketedupdated 2mo agoby $ACAD ACADIA PHARMACEUTICALS INC
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rett syndrome and 5 investigational indications.
all catalysts(7)
approval · 7
Mar 10, 2023
approval
DAYBUE (TROFINETIDE) — FDA approval
trofinetide
→
Sep 30, 2024
approval
DAYBUE (TROFINETIDE) — FDA approval
trofinetide
→
Sep 30, 2024
approval
DAYBUE (TROFINETIDE) — FDA approval
trofinetide
→
Aug 5, 2025
approval
DAYBUE (TROFINETIDE) — FDA approval
trofinetide
→
Aug 5, 2025
approval
DAYBUE (TROFINETIDE) — FDA approval
trofinetide
→
Dec 11, 2025
approval
DAYBUE STIX (TROFINETIDE) — FDA approval
trofinetide
→
Mar 27, 2026
approval
DAYBUE (TROFINETIDE) — FDA approval
trofinetide
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that